Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03522077 · ClinicalTrials.gov registry record · NA
RAVE: Radial Artery Vascular Complication and Resource Utilization
A NA study, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- NA
- Development phase
- 300
- Enrollment target
NCT03522077: Completed NA study, sponsored by Wake Forest University Health Sciences.
NCT03522077 is a NA study that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 300 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (79% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03522077, a NA study, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- NA
- Development phase
- 300 participants
- Enrollment target
Study Summary
The primary objective of this study is to determine if there is a reduction in time to hemostasis in subjects treated with SoftSeal®-STF hemostatic pad when used in conjunction with a vascular compression device after radial transcatheter procedure.
Primary Outcome
Time interval in minutes beginning with sheath removal and ending with removal of hemostatic device and/or observed hemostasis
Interventions
- DEVICE RadAR EasyCLik plus ®-STF hemostatic pad
- DEVICE TR BAND® Compression device plus ®-STF hemostatic pad
- DEVICE SoftSeal®-STF hemostatic pad
- DEVICE VascBand™ Hemostat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2018-05-09 |
| Est. Completion | 2021-12-01 |
| Phase | NA |
What the finished NCT03522077 record still lists
NCT03522077 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (79% lower).
The record links to 0 conditions, and to 4 interventions - of which RadAR EasyCLik plus ®-STF hemostatic pad is the first listed.
NCT03522077 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03522077 about?
NCT03522077 is a clinical study titled "RAVE: Radial Artery Vascular Complication and Resource Utilization". The primary objective of this study is to determine if there is a reduction in time to hemostasis in subjects treated with SoftSeal®-STF hemostatic pad when used in conjunction with a vascular compression device after radial transcatheter procedure.
What is the current status of trial NCT03522077?
This trial is currently completed. It is a NA study. The enrollment target is 300 participants. The study started on 2018-05-09. Estimated completion is 2021-12-01.
What interventions are being tested in trial NCT03522077?
The interventions under investigation include: RadAR EasyCLik plus ®-STF hemostatic pad (DEVICE), TR BAND® Compression device plus ®-STF hemostatic pad (DEVICE), SoftSeal®-STF hemostatic pad (DEVICE), VascBand™ Hemostat (DEVICE).
Who is sponsoring clinical trial NCT03522077?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03522077's enrollment target sits among peer trials
300 330th of 2000 higher than 1,630 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI